Why the study?
Are short-acting calcium channel blockers and their concurrent use with magnesium sulfate associated with adverse safety outcomes in obstetrics and gynecology?
Population
Patients in obstetrics and gynecology, including pregnant women and older hypertensive patients
Design
Review
Authors
Loading...
May warrant caution with short-acting CCBs and magnesium co-use in obstetrics; leaves open confirmation in prospective trials.
Are short-acting calcium channel blockers and their concurrent use with magnesium sulfate associated with adverse safety outcomes in obstetrics and gynecology?
Short-acting calcium channel blockers should be avoided in favor of long-acting varieties in obstetrics and gynecology, and concurrent use with magnesium sulfate requires caution due to potential cardiac toxicity.
Davis et al. (1997) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: